The Relationship of Glucokinase Activator–induced Hypoglycemia with Arteriopathy, Neuronal Necrosis, and Peripheral Neuropathy in Nonclinical Studies

Discovery of Piragliatin—First Glucokinase Activator Studied in Type 2 Diabetic Patients

(2012) Ramakanth Sarabu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Evidence for the Nitric Oxide Pathway as a Potential Mode of Action in Fenoldopam-induced Vascular Injury

(2012) David A. Brott et al.   TOXICOLOGIC PATHOLOGY

Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

(2011) Jeffrey A. Pfefferkorn et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effects of Modulating In Vivo Nitric Oxide Production on the Incidence and Severity of PDE4 Inhibitor–Induced Vascular Injury in Sprague-Dawley Rats

(2011) Christopher M. Sheth et al.   TOXICOLOGICAL SCIENCES

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

(2011) Jeffrey A. Pfefferkorn et al.   MedChemComm

Effects of Acute Hypoglycemia on Inflammatory and Pro-atherothrombotic Biomarkers in Individuals With Type 1 Diabetes and Healthy Individuals

(2010) N. Gogitidze Joy et al.   DIABETES CARE

Hypoglycemia, Diabetes, and Cardiovascular Events

(2010) C. V. Desouza et al.   DIABETES CARE

Glucokinase activators in diabetes management

(2008) Matthew Coghlan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS